{"id":"W2951153020","doi":"10.1097/01.hs9.0000561560.35825.0d","title":"S820 FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3‐YEAR UPDATE OF THE ECHELON‐1 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"ABVD; Dacarbazine; Procarbazine; Medicine; Brentuximab vedotin; Vinblastine; Bleomycin; Vincristine; Internal medicine; Oncology; Population; Chemotherapy; Lymphoma; Cyclophosphamide; Hodgkin lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001477914,0.0002521946,0.0005583807,0.00002108067,0.00006096227,0.00001715203,0.0001592,0.00008967309,0.000657254],"category_scores_gemma":[0.00001764609,0.0001379474,0.0001899106,0.0001569191,0.00006569613,0.00004763383,0.00005814566,0.00006609437,0.00007063794],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001625219,"about_ca_system_score_gemma":0.0002135477,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007005339,"about_ca_topic_score_gemma":0.0001026381,"domain_scores_codex":[0.9985512,0.00004439962,0.0003043838,0.0003950254,0.0003855567,0.0003194008],"domain_scores_gemma":[0.9988144,0.00008833867,0.0001721608,0.0007205291,0.0001081195,0.00009644569],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003609193,0.012589,0.9539768,0.0003176646,0.0009036821,0.0000397398,0.0008276053,0.00002469341,0.001080286,0.001147109,0.008015594,0.01746861],"study_design_scores_gemma":[0.1227272,0.00797488,0.7414531,0.0004978359,0.000862591,0.00004467183,0.0042129,0.0006918722,0.05405998,0.0000991072,0.06679668,0.0005792155],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935526,0.0002819267,0.00008813913,0.001860171,0.0001311631,0.00257214,0.00005086912,0.00004585661,0.001417127],"genre_scores_gemma":[0.9922723,0.0000255101,0.001859401,0.000449728,0.00009140243,0.0001573033,0.00002408152,0.00005664977,0.005063591],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2125237,"threshold_uncertainty_score":0.719647,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00953334348027245,"score_gpt":0.2523886075679352,"score_spread":0.2428552640876628,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}